English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 56552/90363 (63%)
造訪人次 : 11824932      線上人數 : 143
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library & TKU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: http://tkuir.lib.tku.edu.tw:8080/dspace/handle/987654321/93104

    題名: Inhibition of Glycine Transporter-I as a Novel Mechanism for the Treatment of Depression
    作者: Huang, Chih-Chia;Wei, I-Hua;Huang, Chieh-Liang;Chen, Kuang-Ti;Tsai, Mang-Hung;Tsai, Priscilla;Tun, Rene;Huang, Kuo-Hao;Chang, Yue-Cune;Lane, Hsien-Yuan;Tsai, Guochuan Emil
    貢獻者: 淡江大學數學學系
    關鍵詞: Anxiety;elevated plus maze;forced swimming test;glutamate;N-methyl-D-aspartate;sarcosine
    日期: 2013-11-01
    上傳時間: 2013-11-21 13:57:08 (UTC+8)
    出版者: Philadelphia: Elsevier Inc.
    摘要: Background
    Antidepressants, aiming at monoaminergic neurotransmission, exhibit delayed onset of action, limited efficacy, and poor compliance. Glutamatergic neurotransmission is involved in depression. However, it is unclear whether enhancement of the N-methyl-D-aspartate (NMDA) subtype glutamate receptor can be a treatment for depression.

    We studied sarcosine, a glycine transporter-I inhibitor that potentiates NMDA function, in animal models and in depressed patients. We investigated its effects in forced swim test, tail suspension test, elevated plus maze test, novelty-suppressed feeding test, and chronic unpredictable stress test in rats and conducted a 6-week randomized, double-blinded, citalopram-controlled trial in 40 patients with major depressive disorder. Clinical efficacy and side effects were assessed biweekly, with the main outcomes of Hamilton Depression Rating Scale, Global Assessment of Function, and remission rate. The time course of response and dropout rates was also compared.

    Sarcosine decreased immobility in the forced swim test and tail suspension test, reduced the latency to feed in the novelty-suppressed feeding test, and reversed behavioral deficits caused by chronic unpredictable stress test, which are characteristics for an antidepressant. In the clinical study, sarcosine substantially improved scores of Hamilton Depression Rating Scale, Clinical Global Impression, and Global Assessment of Function more than citalopram treatment. Sarcosine-treated patients were much more likely and quicker to remit and less likely to drop out. Sarcosine was well tolerated without significant side effects.

    Our preliminary findings suggest that enhancing NMDA function can improve depression-like behaviors in rodent models and in human depression. Establishment of glycine transporter-I inhibition as a novel treatment for depression waits for confirmation by further proof-of-principle studies.
    關聯: Biological Psychiatry 74(10), pp.734-741
    DOI: 10.1016/j.biopsych.2013.02.020
    顯示於類別:[數學學系暨研究所] 期刊論文


    檔案 描述 大小格式瀏覽次數



    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library & TKU Library IR teams. Copyright ©   - 回饋